About

WHO WE ARE

Founded in 2018, we are an international leader in the development of in-vivo biomarkers to guide targeted therapies in oncology.

OUR MISSION

We develop in-vivo biomarkers transforming oncology, guiding treatment selection and monitoring, improving patients’ pathway and quality of life. ​Within a Positron Emission Tomography exam (PET Scan), biomarkers help oncologists and nuclear medicine physicians personalize the treatment, based on whole body imaging providing the localization and characteristics of tumors.

MEET OUR TEAM

Meet our team of experts in in-vivo biomarkers for oncology with strong competencies in executive leadership, R&D, industry regulations and operations:

Bernard Landes

Chairman & CEO

Former General Manager of Cyclopharma with 25 years of experience in pharmaceutical industry and IT

Peter Webner

CEO, US

Former General Manager of Zevacor Pharma with 25 years of experience in radiopharmaceutical industry

Jean-Bernard Deloye

Head of Market Access

Former Deputy General Manager of Cyclopharma with 25 years of experience in radiopharmaceutical industry

Yann Bouvet

Head of R&D

Former Pharmaceutical and Industrial Development Director of Cyclopharma with 10 years of experience in R&D projects

Jerome Francillard

CFO

Former CFO of Energy Pool with 15 years of experience in consulting and financing growth

Together, we are dedicated to

transforming oncology >

WITH THE SUPPORT OF

European Union